Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028437 | 0.85 | LMNA (0.40) | LMNAPARP1ALDH1A1PKMMEN1 | |
| SCHEMBL6142360 | 0.83 | LMNA (0.40) | LMNAPARP1ALDH1A1PKMMEN1 | |
| SCHEMBL27269511 | 0.79 | PDPK1 (0.40) | LMNAPARP1ALDH1A1PKMMEN1 | |
| SCHEMBL7028440 | 0.78 | PARP1 (0.38) | LMNAPARP1ALDH1A1PKMMEN1 | |
| SCHEMBL6142162 | 0.76 | PARP1 (0.43) | PARP1VCPPTGES | |
| SCHEMBL6142539 | 0.75 | PDPK1 (0.30) | MEN1KMT2A | |
| Bromide SCHEMBL6142159 | 0.74 | — | — | |
| SCHEMBL6142180 | 0.73 | CYP3A4 (0.48) | LMNAPARP1ALDH1A1MEN1KMT2A | |
| SCHEMBL27434863 | 0.72 | PARP1 (0.33) | PARP1MEN1KMT2A | |
| SCHEMBL7206716 | 0.70 | NPC1 (0.33) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944604-B1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2005-01-12 | — | — | EP | claimed |
| US-20020128481-A1 | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | CUPPS THOMAS LEE (US) | 2002-09-12 | — | — | US | claimed |
| US-6225331-B1 | FOR THERAPY AND PROPHYLAXIS NASAL CONGESTION, OTITIS MEDIA, AND SINUSITIS, TREATING COUGH, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR ASTHMA, BENIGN PROSTATIC HYPERTROPHY, CARDIOVASCULAR DISORDERS, GLAUCOMA, HYPEREMIA, CONJUNCTIVITIS | THE PROCTER & GAMBLE COMPANY | 2001-05-01 | — | — | US | claimed |
| US-20010000345-A1 | Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2001-04-19 | — | — | US | claimed |
| EP-0944604-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023596-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0944604-B1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20020128481-A1 | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | CUPPS THOMAS LEE (US) | 2002-09-12 | — | — | US | disclosed |
| US-6391878-B2 | COMPOUNDS SUCH AS (4,7-DIMETHYLBENZIMIDAZOL-5-YL)GUANIDINE; TREATING NASAL CONGESTION, OTITIS MEDIA, ASTHMA, PAIN, MIGRAINE, GASTROINTESTINAL DISORDER, ULCER | THE PROCTER & GAMBLE COMPANY | 2002-05-21 | — | — | US | disclosed |
| US-6225331-B1 | FOR THERAPY AND PROPHYLAXIS NASAL CONGESTION, OTITIS MEDIA, AND SINUSITIS, TREATING COUGH, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR ASTHMA, BENIGN PROSTATIC HYPERTROPHY, CARDIOVASCULAR DISORDERS, GLAUCOMA, HYPEREMIA, CONJUNCTIVITIS | THE PROCTER & GAMBLE COMPANY | 2001-05-01 | — | — | US | disclosed |
| US-20010000345-A1 | Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2001-04-19 | — | — | US | disclosed |
| EP-0944604-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023596-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000345-A1 | Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer | ADRB2, ADRA2C, ADRA2B | LMNA 954/4885PARP1 3103/4885ALDH1A1 1083/4885 |
| US-20020128481-A1 | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | ADRB2, ADRA2C, ADRA2A | LMNA 849/4885PARP1 2870/4885ALDH1A1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.